- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:10 | BMS taps Anthropic's Claude for enterprise-wide AI adoption to speed R&D, global workflows | ||
| 18:10 | CG Life appoints Collette Douaihy as chief creative officer as C-suite buildout continues | ||
| 16:11 | Amgen, bidding adieu to CFO, lures Galderma exec with hefty $12.4M bonus | ||
| 16:11 | Gilead inks another deal with Korean API manufacturer Yuhan, this time worth $140M | ||
| 13:10 | Tarsus taps John Cena for its latest Demodex blepharitis campaign | ||
| Di | Roche signs generic Xofluza licensing deal with Medicines Patent Pool for 129 countries | ||
| Di | UCB digs deeper into Bimzelx's psoriatic arthritis win over Skyrizi | ||
| Di | White House adds 600 generic meds to TrumpRx purchasing portal | ||
| Di | Takeda slapped with $885M verdict in pay-for-delay antitrust case | ||
| Mo | Novartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims | ||
| Mo | Supreme Court declines to hear IRA challenges from Novo, AstraZeneca and more | ||
| Mo | Eli Lilly teams up with Caitlin Clark to bounce sports courts into Indianapolis neighborhoods | ||
| Mo | AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too | ||
| Mo | Merck, Kelun score with sac-TMT in endometrial cancer trial | ||
| Mo | Bristol Myers looks at Houston for potential $1B manufacturing plant | ||
| Mo | Daiichi, AstraZeneca's Enhertu breaks into early breast cancer with dual FDA approvals | ||
| Fr | Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod | ||
| Fr | After Makary departure, CDER chief Tracy Beth Hoeeg likely headed out at FDA: report | ||
| Fr | Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast | ||
| Fr | SCOTUS temporarily restores telehealth access to abortion pill mifepristone | ||
| Fr | As biologics dominate biopharma pipelines, manufacturing hurdles trip up new launches: report | ||
| Fr | Health execs persevere in new policy landscape | ||
| Fr | BridgeBio Pharma teams with awareness groups to spotlight ATTR-CM's hidden impact on women | ||
| Do | Eli Lilly delivers $50M boost to UNICEF's pediatric health push | ||
| Do | AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.